eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Original paper

SMAC protein expression as a potent favorable prognostic factor in locally advanced breast cancer

Piotr Pluta, Dorota Jesionek-Kupnicka, Joanna Kubicka-Wołkowska, Agnieszka Pluta, Kamil Brzozowski, Piotr Potemski, Janusz Piekarski, Radzisław Kordek, Arkadiusz Jeziorski

Pol J Pathol 2018; 69 (1): 33-41
Online publish date: 2018/05/07
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Preoperative systemic therapy including neoadjuvant chemotherapy (NCT) is standard treatment in locally advanced breast cancer (LABC), the aim of which is to enable a radical surgery and to reduce the risk of local and distant recurrence. It has been established that NCT in LABC may effectively induce apoptosis. The study objective was to assess the role of a proapoptotic second mitochondria-derived activator of apoptosis (SMAC) in LABC.

The study group comprised 56 patients with advanced non-metastatic breast cancer (stage IIB –node positive and III), who received NCT followed by surgery and adjuvant treatment. Expression of SMAC protein was analysed using the immunohistochemistry technique in core biopsies sampled from the patients’ breasts before NCT and in surgical specimens collected after completion of NCT. Expression of SMAC was significantly higher in the breast cancer specimens after NCT

(p < 0.01). High expression of SMAC in the core biopsy before NCT correlated with a pathological complete remission (pCR, p < 0.01). The patients with a high expression of SMAC in the surgical specimens after NCT had longer DFS.

Our study proves a potential role of SMAC expression in LABC as a novel favourable prognostic factor in LABC for pCR and disease-free survival (DFS).

locally advanced breast cancer, chemotherapy, SMAC protein

National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/.
Newman LA. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol 2009; 19: 195-203.
Moulder S. Intrinsic resistance to chemotherapy in breast cancer. Women’s Health (Lond) 2010; 6: 821-830.
Krzakowski M, Jassem J (eds.) Rak piersi. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych — 2013 r. Krzakowski M, Warzocha K (eds.). Via Medica, Gdańsk 2013; 246-248.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172.
National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Breast cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, Access 04.2016.
Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther 2014; 144: 82-95.
Du C, Fang M, Li Y, Li L, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
Verhagen AM, Vaux DL. Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis 2002; 7: 163-166.
Yoo NJ, Kim HS, Kim SY, et.al. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS 2003; 111: 382-388.
Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res 2010; 34: 1308-1313.
Pluta P, Cebula-Obrzut B, Ehemann V, et al. Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 2011; 58: 430-435.
TNM Classification of Malignant Tumours. Sobin LH, Gospodarowicz MK, Wittekind C (eds.). 7th ed. Wiley-Blackwell 2009; 181-193.
Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12: 6643-6651.
Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
Wolff AC, Hammond ME, Hicks DG, et al. American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
Kolacinska A, Cebula-Obrzut B, Pakula L, et al. Immune checkpoints: cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. Oncol Lett 2015; 10: 1079-1086.
Cohen J. Statistical power analysis for the behavioural sciences, 2nd ed. Lawrence Erlbaum, New Jersey 1988.
Li D, Yao Q, Li L, Wang L, et al. Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 2007; 6: 1442-1448.
Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008; 7: 60.
Zhao YC, Wang Y, Ni XJ, et al. Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline based neoadjuvant chemotherapy. Mol Med Rep 2014; 92: 614-620.
Palma G, Frasci G, Chirico A, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 2015; 6: 26560-26574.
Montagna E, Bagnardi V, Rotmensz N, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010; 124: 689-699.
Lv Q, Meng Z, Yu Y, et al. Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer. Int J Mol Sci 2016; 17: E2095.
Erbes T, Stickeler E, Rücker G, et al. BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer 2016; 16: 119-132.
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
Jin G, Lan Y, Han F, et al. Smac mimetic-induced caspase-independent necroptosis requires RIP1 in breast cancer. Mol Med Rep 2016; 13: 359-366.
Benetatos CA, Mitsuuchi Y, Burns JM, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-B activation, and is active in patient-derived xenograft models. Mol Cancer Ther 2014; 13: 867-879.
Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Ann Rev Med 2014; 65: 139-155.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe